Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenebrutinib - Genentech

Drug Profile

Fenebrutinib - Genentech

Alternative Names: GDC-0853; RG 7845; RO 7010939

Latest Information Update: 26 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Antirheumatics; Piperazines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
  • No development reported Autoimmune disorders
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 26 Nov 2019 Genentech terminates Phase-II clinical trials in Urticaria (Treatment-resistant) in Canada, Germany and USA (PO) (NCT03693625)
  • 20 Nov 2019 Genentech completes a phase II extension trial for Systemic Lupus Erythematosus in Argentina, Brazil, Bulgaria, Chile, Colombia, Portugal, South Korea, Mexico, Spain, Taiwan, United Kingdom and USA (PO)(NCT03407482) (EudraCT2017-001764-37)
  • 08 Nov 2019 Adverse events and efficacy data from a phase II trial in rheumatoid arthritis were presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top